top of page

RESTORING BALANCE

WITH POWERFUL SCIENCE

Creating a New Paradigm in Gene Therapy Delivery to Address Chronic Inflammation 

Xalud Therapeutics is a clinical-stage biotechnology company advancing a non-viral plasmid DNA (pDNA)-delivered gene therapy platform to treat pathologic inflammation by restoring homeostasis in the immune system. Xalud’s initial approach is focused on harnessing the power of interleukin-10 (IL-10), a potent cytokine that acts as a master regulator for multiple inflammatory pathways, to address the root cause of inflammation in several chronic inflammatory indications with a high unmet need. This includes programs in both musculoskeletal and neurodegenerative diseases. Xalud’s lead candidate, XT-150, is a patent-protected, locally injectable pDNA-delivered gene therapy expressing IL-10v, a proprietary modified version of IL-10.  

OUR
MISSION

A healthy, strong body lives in a state of equilibrium.  Every day, it detects potential signals of injury or disease progression and naturally regulates its immune system by finely balancing anti-inflammatory cytokines and pro-inflammatory mediators. Unfortunately, when the body’s immune system is unable to self-regulate, inflammation can persist and progress over long periods of time. This continuous cycle of immune dysregulation leads to damaged cells, tissue death, and the resulting symptoms seen in a broad range of diseases. We seek to transform the treatment of chronic inflammatory disease with a novel gene therapy that addresses the underlying cause of disease, as opposed to merely masking its symptoms, to help ameliorate the high burden on patient lives. 


Read More >

A healthy, strong body lives in a state of equilibrium.  Every day, it detects potential signals of injury or disease progression and naturally regulates its immune system by finely balancing anti-inflammatory cytokines and pro-inflammatory mediators. Unfortunately, when the body’s immune system is unable to self-regulate, inflammation can persist and progress over long periods of time. This continuous cycle of immune dysregulation leads to damaged cells, tissue death, and the resulting symptoms seen in a broad range of diseases. We seek to transform the treatment of chronic inflammatory disease with a novel gene therapy that addresses the underlying cause of disease, as opposed to merely masking its symptoms, to help ameliorate the high burden on patient lives. 

Read More >

OUR
SCIENCE

Our proprietary non-viral pDNA-delivered gene therapy platform offers adaptability and the potential to safely deliver transgenes to patients with a wide range of chronic inflammatory, neurological, and autoimmune diseases. Importantly, the technology potentially expands the capabilities and access of gene therapy beyond rare monogenic conditions to highly prevalent diseases. This non-immunogenic and non-integrating platform is designed for durable and safe local expression with the potential for redosing. Our lead candidate, XT-150, uses pDNA technology to deliver a proprietary version of IL-10 (IL-10v). IL-10, a potent anti-inflammatory cytokine, plays a critical role in balancing local immune responses to mitigate inflammation.  

Read More >

Our proprietary non-viral pDNA-delivered gene therapy platform offers adaptability and the potential to safely deliver transgenes to patients with a wide range of chronic inflammatory, neurological, and autoimmune diseases. Importantly, the technology potentially expands the capabilities and access of gene therapy beyond rare monogenic conditions to highly prevalent diseases. This non-immunogenic and non-integrating platform is designed for durable and safe local expression with the potential for redosing. Our lead candidate, XT-150, uses pDNA technology to deliver a proprietary version of IL-10 (IL-10v). IL-10, a potent anti-inflammatory cytokine, plays a critical role in balancing local immune responses to mitigate inflammation.  

Read More >

OUR
PIPELINE

Chronic inflammatory conditions can damage multiple organ systems (including joints, nerves, skin, eyes, and the digestive system) and can have profound negative impacts on health through loss of strength and function. To reflect this extensive unmet need spanning multiple diseases, we are evaluating our lead therapeutic candidate, XT-150, across multiple treatment indications in preclinical and clinical studies. We have completed a Phase 2b trial for the use of XT-150 in osteoarthritis of the knee and have sponsored an ongoing Ph1/2a trial in facet joint syndrome, which impacts the back and neck. Xalud has also conducted preclinical studies demonstrating potential therapeutic benefit across several disease areas and modes of delivery, including in amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), neuropathic pain, and uveitis. Next-generation development is focused on expanding tissue targeting specificity and customized delivery to broaden disease targets.  

Read More >

Chronic inflammatory conditions can damage multiple organ systems (including joints, nerves, skin, eyes, and the digestive system) and can have profound negative impacts on health through loss of strength and function. To reflect this extensive unmet need spanning multiple diseases, we are evaluating our lead therapeutic candidate, XT-150, across multiple treatment indications in preclinical and clinical studies. We have completed a Phase 2b trial for the use of XT-150 in osteoarthritis of the knee and have sponsored an ongoing Ph1/2a trial in facet joint syndrome, which impacts the back and neck. Xalud has also conducted preclinical studies demonstrating potential therapeutic benefit across several disease areas and modes of delivery, including in amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), neuropathic pain, and uveitis. Next-generation development is focused on expanding tissue targeting specificity and customized delivery to broaden disease targets.  

Read More >

bottom of page